Copyright (c) 2022 AJC
This work is licensed under a Creative Commons Attribution 4.0 International License.
Synthesis and Structural Characterization of Process Related Impurities of Mirabegron: A Beta-3 Adrenergic Agonist Drug
Corresponding Author(s) : Sudheer Kumar Reddy Gopa
Asian Journal of Chemistry,
Vol. 34 No. 11 (2022): Vol 34 Issue 11, 2022
Abstract
In the synthesis of active pharmaceutical ingredient and the development of pharmaceutical products, the impurities profiling plays a significant role. The control of impurities is essential for producing the quality, safe and efficient drug products for therapeutic use. Few works reported for the synthesis of potential impurities and further characterized to support the synthesis route and purity of the synthesized compound. Hence in present study, five impurities of mirabegron such as impurity 3, 4, 6, 8 and 9 were synthesized and structural characterization was carried using NMR, IR and mass spectral studies. Based on the results, it was confirmed that the route of synthesis established in the study was simple, convenient and economical and can be useful for the products of potential impurities of mirabegron. By characterizing each of these impurities, the regulatory need has been met. Additionally, the analytical method development and validation studies have utilized the generated impurity standards. This effort helped with the process development’s optimization stage and made it possible to identify the crucial parts of the process. The production method for mirabegron was carefully adjusted to eliminate or reduce the formation of impurities, which is helpful for the creation of safe pharmaceutical goods.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- O. Yamaguchi and C.R. Chapple, Neurourol. Urodyn., 26, 752 (2007); https://doi.org/10.1002/nau.20420
- T. Takasu, M. Ukai, S. Sato, T. Matsui, I. Nagase, T. Maruyama, M. Sasamata, K. Miyata, H. Uchida and O. Yamaguchi, J. Pharmacol. Exp. Ther., 321, 642 (2007); https://doi.org/10.1124/jpet.106.115840
- C.R. Chapple, L. Cardozo, V.W. Nitti, E. Siddiqui and M.C. Michel, Neurourol. Urodyn., 33, 17 (2014); https://doi.org/10.1002/nau.22505
- T.-F. Chen, H.-C. Huang, Y.-H. Lin, C.-H. Liao and B.-J. Chiang, Urol. Sci., 28, 162 (2017); https://doi.org/10.1016/j.urols.2017.05.006
- S. Gorog, J. Pharm. Biomed. Anal. J., 48, 247 (2008); https://doi.org/10.1016/j.jpba.2007.10.038
- ICH Harmonised Tripartite Guideline, Impurities in New Drug Substances Q3A(R2), In Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, 25 October (2006).
- H.K. Chandrawanshi, U. Pilaniya, P. Manchandani, P. Jain, N. Singh and K. Pilaniya, J. Adv. Pharm. Technol. Res., 1, 302 (2010); https://doi.org/10.4103/0110-5558.72422
- R. Vedanthama, B. Kandagatla, S. Vyala, V.V.N.K.V. Prasada Raju, P. Cherukupalli, J. Iqbal, V.H. Dahanukar, M. Kagga, R. Bandichhor and S. Oruganti, J. Chem. Pharm., 7, 1473 (2015).
- T. Bharathi and G.D.G. Bhadre, Am. J. Pharm. Health Res., 9, 2 (2021).
- S.R. Ganpisetti, K. Basavaiah, R.P. Sunil, L. Kalyanaraman, B.M. Rao and S. Rajkumar, Int. J. Pharm. Bio. Sci., 12, 1 (2021).
- J. Lin, T. Huang, M. Feng, D. Li, D. Zhao, J. Wang, J. Jin, W. Zhu and M. Li, J Pharm. Biomed. Anal. J., 168, 181 (2019); https://doi.org/10.1016/j.jpba.2019.01.045
- S. Parsha, Y. Ravindra Kumar, M. Ravichander, L. Prakash and B. Sudharani, J. Liq. Chromatogr. Relat. Technol., 39, 178 (2016); https://doi.org/10.1080/10826076.2016.1144201
- P.D. Kalariya, T.J. Reddy, M. Sharma, P. Garg, T.J. Reddy, R. Srinivas and M.V.N.K. Talluri, RSC Adv., 5, 31024 (2015); https://doi.org/10.1039/C5RA01711D
References
O. Yamaguchi and C.R. Chapple, Neurourol. Urodyn., 26, 752 (2007); https://doi.org/10.1002/nau.20420
T. Takasu, M. Ukai, S. Sato, T. Matsui, I. Nagase, T. Maruyama, M. Sasamata, K. Miyata, H. Uchida and O. Yamaguchi, J. Pharmacol. Exp. Ther., 321, 642 (2007); https://doi.org/10.1124/jpet.106.115840
C.R. Chapple, L. Cardozo, V.W. Nitti, E. Siddiqui and M.C. Michel, Neurourol. Urodyn., 33, 17 (2014); https://doi.org/10.1002/nau.22505
T.-F. Chen, H.-C. Huang, Y.-H. Lin, C.-H. Liao and B.-J. Chiang, Urol. Sci., 28, 162 (2017); https://doi.org/10.1016/j.urols.2017.05.006
S. Gorog, J. Pharm. Biomed. Anal. J., 48, 247 (2008); https://doi.org/10.1016/j.jpba.2007.10.038
ICH Harmonised Tripartite Guideline, Impurities in New Drug Substances Q3A(R2), In Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, 25 October (2006).
H.K. Chandrawanshi, U. Pilaniya, P. Manchandani, P. Jain, N. Singh and K. Pilaniya, J. Adv. Pharm. Technol. Res., 1, 302 (2010); https://doi.org/10.4103/0110-5558.72422
R. Vedanthama, B. Kandagatla, S. Vyala, V.V.N.K.V. Prasada Raju, P. Cherukupalli, J. Iqbal, V.H. Dahanukar, M. Kagga, R. Bandichhor and S. Oruganti, J. Chem. Pharm., 7, 1473 (2015).
T. Bharathi and G.D.G. Bhadre, Am. J. Pharm. Health Res., 9, 2 (2021).
S.R. Ganpisetti, K. Basavaiah, R.P. Sunil, L. Kalyanaraman, B.M. Rao and S. Rajkumar, Int. J. Pharm. Bio. Sci., 12, 1 (2021).
J. Lin, T. Huang, M. Feng, D. Li, D. Zhao, J. Wang, J. Jin, W. Zhu and M. Li, J Pharm. Biomed. Anal. J., 168, 181 (2019); https://doi.org/10.1016/j.jpba.2019.01.045
S. Parsha, Y. Ravindra Kumar, M. Ravichander, L. Prakash and B. Sudharani, J. Liq. Chromatogr. Relat. Technol., 39, 178 (2016); https://doi.org/10.1080/10826076.2016.1144201
P.D. Kalariya, T.J. Reddy, M. Sharma, P. Garg, T.J. Reddy, R. Srinivas and M.V.N.K. Talluri, RSC Adv., 5, 31024 (2015); https://doi.org/10.1039/C5RA01711D